Infanrix hexa + Menitorix + Synflorix

This drug entry refers to a pediatric vaccination regimen developed by **GSK**, involving the co-administration of **Infanrix hexa**, **Menitorix**, and a **pneumococcal conjugate vaccine** (specifically **Synflorix**, also known as GSK1024850A). Infanrix hexa is a hexavalent vaccine providing active immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib). Menitorix is a combined vaccine targeting Hib and Neisseria meningitidis serogroup C. Synflorix is a decavalent vaccine targeting ten serotypes of Streptococcus pneumoniae. This combination is used in clinical trials (e.g., NCT00707733) to evaluate the long-term persistence of antibodies against meningococcal, Hib, pneumococcal, and hepatitis B antigens in children who have completed their primary and booster vaccination series.

Brand names

Infanrix hexaMenitorixSynflorix

Other names

Infanrix hexa-GlaxoSmithKline-meningococcal meningitis-Haemophilus influenzae type b infection-pneumococcal infection-hepatitis BDTPa-HBV-IPV/Hib + Hib-MenC + PCV10